Mabwell Initiates Phase III Clinical Study of its Nectin-4-Targeting ADC 9MW2821 for the Treatment of Triple-Negative Breast Cancer

B SHANGHAI, April 23, 2026 /PRNewswire/ — Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announces the initiation of a Phase…
posteditor
posteditor
Articles: 27509

Other News